1. MHRA. Evusheld approved to prevent covid-19 in people whose immune response is poor. Mar 2022. https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor.
2. MHRA. Regulatory approval of Evusheld (tixagevimab/cilgavimab). Mar 2022. https://www.gov.uk/government/publications/regulatory-approval-of-evusheld-tixagevimabcilgavimab.
3. Covid-19: UK will not buy Evusheld owing to “insufficient data” on protection, government says
4. Drug Safety Research Unit. Open letter to the Right Honourable Dr Thérèse Coffey MP, Secretary of State for Health and Social Care: Proposal to facilitate the use of Evusheld as a pre-exposure prophylactic treatment against COVID19 disease in clinically extremely vulnerable individuals in the UK. Sep 2022. https://www.dsru.org/wp-content/uploads/2022/09/Evusheld-Open-Letter-Sept-2022-final.pdf.
5. Department of Health and Social Care. RAPID C-19 Oversight Group report: review of Evusheld—summary. Oct 2022. https://www.gov.uk/government/publications/rapid-c-19-oversight-group-report-to-chief-medical-officer-review-of-evusheld/rapid-c-19-oversight-group-report-to-chief-medical-officer-summary.